310 related articles for article (PubMed ID: 20651383)
1. The impact of the extent of lymph-node dissection on biochemical relapse after radical prostatectomy in node-negative patients.
Schiavina R; Bertaccini A; Franceschelli A; Manferrari F; Vagnoni V; Borghesi M; Morselli-Labate AM; Martorana G
Anticancer Res; 2010 Jun; 30(6):2297-302. PubMed ID: 20651383
[TBL] [Abstract][Full Text] [Related]
2. The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer.
Schiavina R; Manferrari F; Garofalo M; Bertaccini A; Vagnoni V; Guidi M; Borghesi M; Baccos A; Morselli-Labate AM; Concetti S; Martorana G
BJU Int; 2011 Oct; 108(8):1262-8. PubMed ID: 21446934
[TBL] [Abstract][Full Text] [Related]
3. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
Bhatta-Dhar N; Reuther AM; Zippe C; Klein EA
Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
[TBL] [Abstract][Full Text] [Related]
4. Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer.
Weight CJ; Reuther AM; Gunn PW; Zippe CR; Dhar NB; Klein EA
Urology; 2008 Jan; 71(1):141-5. PubMed ID: 18242383
[TBL] [Abstract][Full Text] [Related]
5. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.
Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P
Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184
[TBL] [Abstract][Full Text] [Related]
7. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
8. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
[TBL] [Abstract][Full Text] [Related]
9. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
Kupelian P; Katcher J; Levin H; Zippe C; Klein E
Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
[TBL] [Abstract][Full Text] [Related]
10. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
12. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
13. Differing risk of cancer death among patients with lymph node metastasis after radical prostatectomy and pelvic lymph node dissection: identification of risk categories according to number of positive nodes and Gleason score.
Schiavina R; Borghesi M; Brunocilla E; Manferrari F; Fiorentino M; Vagnoni V; Baccos A; Pultrone CV; Rocca GC; Rizzi S; Martorana G
BJU Int; 2013 Jun; 111(8):1237-44. PubMed ID: 23331345
[TBL] [Abstract][Full Text] [Related]
14. Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy.
Walz J; Chun FK; Klein EA; Reuther A; Graefen M; Huland H; Karakiewicz PI
Eur Urol; 2009 Feb; 55(2):412-19. PubMed ID: 19027223
[TBL] [Abstract][Full Text] [Related]
15. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of surgical margin status for biochemical recurrence following radical prostatectomy.
Hashimoto K; Masumori N; Takei F; Fukuta F; Takahashi A; Itoh N; Hasegawa T; Tsukamoto T
Jpn J Clin Oncol; 2008 Jan; 38(1):31-5. PubMed ID: 18203710
[TBL] [Abstract][Full Text] [Related]
17. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era.
Isbarn H; Wanner M; Salomon G; Steuber T; Schlomm T; Köllermann J; Sauter G; Haese A; Heinzer H; Huland H; Graefen M
BJU Int; 2010 Jul; 106(1):37-43. PubMed ID: 20002667
[TBL] [Abstract][Full Text] [Related]
18. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.
Eggener SE; Roehl KA; Smith ND; Antenor JA; Han M; Catalona WJ
J Urol; 2005 Apr; 173(4):1150-5. PubMed ID: 15758725
[TBL] [Abstract][Full Text] [Related]
19. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer.
Briganti A; Joniau S; Gontero P; Abdollah F; Passoni NM; Tombal B; Marchioro G; Kneitz B; Walz J; Frohneberg D; Bangma CH; Graefen M; Tizzani A; Frea B; Karnes RJ; Montorsi F; Van Poppel H; Spahn M
Eur Urol; 2012 Mar; 61(3):584-92. PubMed ID: 22153925
[TBL] [Abstract][Full Text] [Related]
20. Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer.
Briganti A; Capitanio U; Chun FK; Gallina A; Suardi N; Salonia A; Da Pozzo LF; Colombo R; Di Girolamo V; Bertini R; Guazzoni G; Karakiewicz PI; Montorsi F; Rigatti P
Eur Urol; 2008 Oct; 54(4):794-802. PubMed ID: 18514383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]